Investor Calendar is powered by PrecisionIR, the leading webcaster of official investor relations events, and offers free access to live and archived corporate communications
 
  Home     Calendar     Conferences     Roadshows     Forums     Alerts     Research     Support     Podcast  
  Novelos Therapeutics, Inc. (NVLT) www.novelos.com
Novelos Therapeutics, Inc.

Enter your email address to receive alerts about this company
Help
June 28, 2012 - 12:30 PM Eastern
LHA Life Sciences & Medical Technologies Virtual Conference


Press Release
      More company presentations from
                   

Harry S. Palmin, President and CEO, Director

Mr. Palmin has served as our president and a director since 1998 and our chief executive officer since January 2005. From 1998 to September 2005, he served as our acting chief financial officer. From 1996 to 1998, he was a vice president at Lehman Brothers and from 1993 to 1996, he was an associate at Morgan Stanley & Co. Mr. Palmin earned a B.A. in economics and business and a M.A. in international economics and finance from the International Business School at Brandeis University. He has also studied at the London School of Economics and the Copenhagen Business School. Mr. Palmin’s experience managing the funding and development of our product candidates for 13 years and his knowledge of capital markets are strong qualifications to serve on our board of directors. 		 
 
Information contained in this webcast is current as of the date and time first presented. The use of pop-up blocking or firewall software may prevent you from accessing this webcast. Please temporarily disable any of these products you may have while attempting to access this event.
About The Company
Novelos Therapeutics, Inc. (OTCBB: NVLT) is developing novel drugs for the treatment and diagnosis of cancer. Its lead drug candidates are based on a cancer-targeting technology whereby compounds are selectively taken up and retained in cancer cells (including cancer stem cells) versus normal cells. Thus, Novelos compounds directly kill cancer cells while minimizing harm to normal cells, and offer the potential for a paradigm shift in cancer therapy – efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. More specifically, Novelos’ technology enables targeted delivery to cancer cells of apoptosis-inducing Akt inhibition or, when a radioactive molecule is attached, of radiation sufficient to kill cancer cells. Other labeled variations of its compounds provide imaging agents for an accurate diagnosis of cancer, including metastases, and can also objectively measure therapeutic success. The Company believes this platform is capable of yielding multiple, distinct product opportunities that will “find, treat and follow” cancer anywhere in the body in a novel, highly selective way. For more information, please visit www.novelos.com.

Market Assistant
Earnings Data
Annual Report
Related Events (times are Eastern) Show times in :
Company NameTicker Date/TimeTypeAlertsAudioPodcastVideoSlidesAnnual
Report
Novelos Therapeutics, Inc. NVLT  Jun 28, 2012 
@ 12:30pm 		LHA Life Sciences & Medical Technologies Virtual ConferenceSignup for email alerts about this company's events and news         

Comments or questions? Click Here

Privacy Statement Terms and Conditions


©2000-2013 PrecisionIR. All rights reserved.
   
 

A part of PrecisionIR Group, www.PrecisionIR.com
601 Moorefield Park Drive, Richmond, VA 23236
145 Cannon Street, London, EC4N 5BQ, UK (Registered in England No 2394368)
Strandvägen 7A, 114 56 Stockholm, Sweden